Kriessmann A, Theiss W, Lutilsky L, Wirtzfeld A, Seifert W, Grünberg G
Fortschr Med. 1977 Apr 7;95(13):858-66.
Fibrinolytic therapy was carried out in 59 patients suffering from a total of 60 deep venous thromboses of the iliac segment (n = 24), the femoropopliteal segment (n = 18), the deep calf veins (n = 2), or the subclavian vein (n = 16). 46 patients received streptokinase (SK), 4 were given urokinase (UK), and 10 were treated with streptokinase followed by urokinase (SK + UK). The duration of fibrinolytic therapy was between 19 and 596 hours (x = 166 +/- 111 hrs). Phlebographic examination was used to determine the location of the thrombotic occlusion as well as to evaluate therapeutic results. To assure sufficient anticoagulatory protection during therapy with streptokinase the dose of streptokinase was either reduced by steps of 20,000 U/hr to a minimum of 40,000 U/hr or heparin was added as a continuous infusion. Urokinase was administered with a mean loading dose of 75,000 IU followed by an average maintenance dose of 40,000 IU/hr; it was always given in combination with heparin. When therapeutic success was graded as complete/partial/no recanalisation, the following results were obtained: thrombotic occlusion up to 1 week old 35%/48%/17%; up to 2 weeks old 57%/14%/29%; 3 or 4 weeks old 12%/38%/50%; older than 4 weeks 13%/37%/50%. The two most common side effects were a fall of the hemoglobin and a rise of body temperature. Treatment with SK had to be interrupted for bleeding in two cases. One patient diet after rupture of the liver and of the spleen following development of subcapsular hematoma in these organs, 3 patients survived pulmonary embolism without major long-term impairment. Considering medical and social aspects (preservation of capability for working in young adults) it appears justified to administer fibrinolytic agents up to a thrombus age of 14 days, in some cases even up to a thrombus age of 28 days. Good results in cases of deep vein thrombosis of the lower limbs are often obtained only when fibrinolytic therapy is extended beyond 96 hours. It should be performed in intensive care units only. Follow-up examinations of the venous drainage capacity up to 2 years after fibrinolytic therapy document the good therapeutic effect that is warrented by streptokinase or urokinase induced complete recanalisation.
对59例患者实施了纤维蛋白溶解疗法,这些患者共有60处髂段(n = 24)、股腘段(n = 18)、小腿深静脉(n = 2)或锁骨下静脉(n = 16)的深静脉血栓形成。46例患者接受了链激酶(SK)治疗,4例给予尿激酶(UK),10例先接受链激酶治疗随后接受尿激酶治疗(SK + UK)。纤维蛋白溶解疗法的持续时间为19至596小时(x = 166 +/- 111小时)。静脉造影检查用于确定血栓性阻塞的位置以及评估治疗效果。为确保在链激酶治疗期间有足够的抗凝保护,链激酶的剂量以每小时20,000 U的步长递减至最低40,000 U/小时,或者添加肝素进行持续输注。尿激酶的平均负荷剂量为75,000 IU,随后平均维持剂量为40,000 IU/小时;它总是与肝素联合使用。当将治疗成功分为完全/部分/未再通时,获得了以下结果:血栓形成至1周龄的患者,完全再通/部分再通/未再通的比例为35%/48%/17%;至2周龄的患者为57%/14%/29%;3或4周龄的患者为12%/38%/50%;4周龄以上的患者为13%/37%/50%。两种最常见的副作用是血红蛋白下降和体温升高。2例患者因出血不得不中断SK治疗。1例患者在这些器官出现包膜下血肿后发生肝脾破裂死亡,3例患者存活,虽发生肺栓塞但无严重的长期损害。考虑到医学和社会方面(保存年轻人的工作能力),在血栓形成14天龄内给予纤维蛋白溶解剂似乎是合理的,在某些情况下甚至在血栓形成28天龄内也合理。下肢深静脉血栓形成的病例通常只有在纤维蛋白溶解疗法延长超过96小时时才会取得良好效果。该疗法应仅在重症监护病房进行。纤维蛋白溶解疗法后长达2年的静脉引流能力随访检查证明了链激酶或尿激酶诱导的完全再通所带来的良好治疗效果。